Filing Details
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event.
8k filedNASDAQ:IKT
Inhibikase Therapeutics, Inc. (IKT) Reports Material Event to SEC
Filing Details Inhibikase Therapeutics, Inc. (NASDAQ:IKT) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event. Market…
Market Context
Inhibikase Therapeutics, Inc.'s stock currently trades at $2.06 with a market capitalization of $108.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Inhibikase Therapeutics, Inc.'s stock.
All SEC filings for Inhibikase Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View IKT Stock Page
Frequently Asked Questions
Where can I read IKT's SEC filings?
Browse all filings on our IKT SEC filings page.
What types of SEC filings does Inhibikase Therapeutics, Inc. file?
Public companies like Inhibikase Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.